In a phase II trial of 18 patients with newly diagnosed Ph+ ALL, dasatinib followed by CD19 and CD22 CAR-T-cell infusions resulted in a complete molecular response in 76.9% of the patients. Here, CD22 is linked to acute lymphoblastic leukemia.